Exclusive Summary

• - No core patent barriers remain; hGH biosimilars have been approved since 2006 in EU/US, enabling price- and channel-led entry across multiple geographies.
• - Pediatric GHD and SGA drive a sizable, steady patient pool (13–37k new GHD cases/year; SGA candidates in the millions), with a US$5–6B market growing mid- to high-single digits.
• - 191-AA sequence, EP/USP/CP/WHO standards, and full presentations (lyophilized, liquid, PFS; 2–16 IU) create adherence and setting coverage advantages.
• - GH is standard or guideline-recommended for key pediatric indications and adult GHD in many countries, while not on the WHO core EML.
• - Typical discounts of 20–40% in developed markets and 30–60% in tenders/self-pay versus originators improve tender competitiveness and access.

Asset Materials

Contact Us for Full Materials